Cargando…

Visceral Leishmaniasis and HIV Co-infection in Bihar, India: Long-term Effectiveness and Treatment Outcomes with Liposomal Amphotericin B (AmBisome)

BACKGROUND: Visceral Leishmaniasis (VL; also known as kala-azar) is an ultimately fatal disease endemic in the Indian state of Bihar, while HIV/AIDS is an emerging disease in this region. A 2011 observational cohort study conducted in Bihar involving 55 VL/HIV co-infected patients treated with 20–25...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burza, Sakib, Mahajan, Raman, Sinha, Prabhat K., van Griensven, Johan, Pandey, Krishna, Lima, María Angeles, Sanz, Marta Gonzalez, Sunyoto, Temmy, Kumar, Sunil, Mitra, Gaurab, Kumar, Ranjeet, Verma, Neena, Das, Pradeep
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4125300/ https://www.ncbi.nlm.nih.gov/pubmed/25101665 http://dx.doi.org/10.1371/journal.pntd.0003053

Ejemplares similares

Post Kala-Azar Dermal Leishmaniasis following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) for Primary Visceral Leishmaniasis in Bihar, India
por: Burza, Sakib, et al.
Publicado: (2014)

Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India
por: Burza, Sakib, et al.
Publicado: (2014)

Five-Year Field Results and Long-Term Effectiveness of 20 mg/kg Liposomal Amphotericin B (Ambisome) for Visceral Leishmaniasis in Bihar, India
por: Burza, Sakib, et al.
Publicado: (2014)

Immediate hypersensitivity reaction following liposomal amphotericin-B (AmBisome) infusion
por: Nath, Proggananda, et al.
Publicado: (2014)

AmBisome Monotherapy and Combination AmBisome–Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 Trial( )
por: Burza, Sakib, et al.
Publicado: (2022)

Effectiveness and Safety of Short Course Liposomal Amphotericin B (AmBisome) as First Line Treatment for Visceral Leishmaniasis in Bangladesh
por: Lucero, Emiliano, et al.
Publicado: (2015)

Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome(®) and AmBisome(®) in murine cutaneous leishmaniasis
por: Wijnant, Gert-Jan, et al.
Publicado: (2018)

A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia
por: Diro, Ermias, et al.
Publicado: (2019)

The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study
por: Abongomera, Charles, et al.
Publicado: (2018)

Single-dose liposomal amphotericin B (AmBisome(®)) for the treatment of Visceral Leishmaniasis in East Africa: study protocol for a randomized controlled trial
por: Edwards, Tansy, et al.
Publicado: (2011)

Cytotoxicity of Amphotericin B and AmBisome: In Silico and In Vivo Evaluation Employing the Chick Embryo Model
por: Khosravi, Ahmad, et al.
Publicado: (2022)

Relation between Skin Pharmacokinetics and Efficacy in AmBisome Treatment of Murine Cutaneous Leishmaniasis
por: Wijnant, Gert-Jan, et al.
Publicado: (2018)

The Viscoelastic Properties of the Fungal Cell Wall Allow Traffic of AmBisome as Intact Liposome Vesicles
por: Walker, Louise, et al.
Publicado: (2018)

A Comparison of AmBisome(®) to Amphotericin B for Treatment of Systemic Candidiasis in Very Low Birth Weight Infants
por: Jeon, Ga Won, et al.
Publicado: (2007)

Tissue-specific transcriptomic changes associated with AmBisome® treatment of BALB/c mice with experimental visceral leishmaniasis
por: Forrester, Sarah, et al.
Publicado: (2019)

Parasitic Loads in Tissues of Mice Infected with Trypanosoma cruzi and Treated with AmBisome
por: Cencig, Sabrina, et al.
Publicado: (2011)

Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh
por: Rahman, Ridwanur, et al.
Publicado: (2017)

Safety and Efficacy of Single Dose versus Multiple Doses of AmBisome® for Treatment of Visceral Leishmaniasis in Eastern Africa: A Randomised Trial
por: Khalil, Eltahir A. G., et al.
Publicado: (2014)

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial
por: Wasunna, Monique, et al.
Publicado: (2016)

Hypokalaemia-Induced Rhabdomyolysis after Treatment of Post-Kala-azar Dermal Leishmaniasis (PKDL) with High-Dose AmBisome in Bangladesh—A Case Report
por: Marking, Ulrika, et al.
Publicado: (2014)

Correction: Five-Year Field Results and Long-Term Effectiveness of 20 mg/kg Liposomal Amphotericin B (Ambisome) for Visceral Leishmaniasis in Bihar, India
Publicado: (2014)

Correction: Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India
Publicado: (2014)

Liposomal amphotericin B as a treatment for human leishmaniasis
por: Balasegaram, Manica, et al.
Publicado: (2012)

Combination Treatment for Visceral Leishmaniasis Patients Coinfected with Human Immunodeficiency Virus in India
por: Mahajan, Raman, et al.
Publicado: (2015)

Community-based management of severe acute malnutrition in India: new evidence from Bihar(1)(2)(3)
por: Burza, Sakib, et al.
Publicado: (2015)

AmBisome Induced Avascular Necrosis of the Alae of the Nose of a very young girl suffering from Kala‐azar – a Case Report
por: Maruf, Shomik, et al.
Publicado: (2016)

Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India
por: Goyal, Vishal, et al.
Publicado: (2018)

Field effectiveness of new visceral leishmaniasis regimens after 1 year following treatment within public health facilities in Bihar, India
por: Goyal, Vishal, et al.
Publicado: (2019)

AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial
por: Lawrence, David S., et al.
Publicado: (2018)

AMBIsome Therapy Induction OptimisatioN (AMBITION): High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: economic evaluation protocol for a randomised controlled trial-based equivalence study
por: Ponatshego, Ponego Lloyd, et al.
Publicado: (2019)

Correction to: AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial
por: Lawrence, David S., et al.
Publicado: (2019)

Prevalence and determinants of asymptomatic Leishmania infection in HIV-infected individuals living within visceral leishmaniasis endemic areas of Bihar, India
por: Mahajan, Raman, et al.
Publicado: (2022)

Visceral Leishmaniasis-HIV Coinfection as a Predictor of Increased Leishmania Transmission at the Village Level in Bihar, India
por: Cloots, Kristien, et al.
Publicado: (2021)

Quality of life perceptions amongst patients co-infected with Visceral Leishmaniasis and HIV: A qualitative study from Bihar, India
por: Nair, Mohit, et al.
Publicado: (2020)

Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease
por: Boelaert, Marleen, et al.
Publicado: (2014)

Liposomal Amphotericin B and Leishmaniasis: Dose and Response
por: Sundar, Shyam, et al.
Publicado: (2010)

AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial
por: Molefi, Mooketsi, et al.
Publicado: (2015)

Visceral leishmaniasis in Somalia: A review of epidemiology and access to care
por: Sunyoto, Temmy, et al.
Publicado: (2017)

Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B
por: Ubals, Maria, et al.
Publicado: (2021)

New insights into leishmaniasis in the immunosuppressed
por: Akuffo, Hannah, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tb64bstsobpu1ig64uij90empj